A carregar...
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
The main curative treatments for hepatocellular carcinoma (HCC) are surgical resection and liver transplantation, which only benefits 15% to 25% of patients. In addition, HCC is highly refractory and resistant to cytotoxic chemotherapy. Although several multi-kinase inhibitors, such as sorafenib, re...
Na minha lista:
| Publicado no: | Biomolecules |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7022495/ https://ncbi.nlm.nih.gov/pubmed/31936661 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10010117 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|